Catalyst Pharmaceuticals Company Insiders

Catalyst Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of 0.1835 % which means that it generated a profit of $0.1835 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2829 %, meaning that it created $0.2829 on every $100 dollars invested by stockholders. Catalyst Pharmaceuticals' management efficiency ratios could be used to measure how well Catalyst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.27 in 2024. Return On Capital Employed is likely to rise to 0.23 in 2024. At this time, Catalyst Pharmaceuticals' Return On Assets are fairly stable compared to the past year. Asset Turnover is likely to rise to 0.89 in 2024, whereas Other Assets are likely to drop 0.95 in 2024. Net Income Applicable To Common Shares is likely to rise to about 100.3 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 57 M in 2024.

Catalyst Pharmaceuticals Workforce Comparison

The company has Profit Margin (PM) of 0.31 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.4 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.4.

Catalyst Pharmaceuticals Insider Trading History

Catalyst Pharmaceuticals Notable Stakeholders

The success or failure of an entity such as Catalyst Pharmaceuticals often depends on how effective the management is. Catalyst Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Catalyst management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Catalyst management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Catalyst Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Catalyst Pharmaceuticals. Check Catalyst Pharmaceuticals' Beneish M Score to see the likelihood of Catalyst Pharmaceuticals' management manipulating its earnings.

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.